Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 13571

1.

A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.

Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR.

Fam Cancer. 2017 May 20. doi: 10.1007/s10689-017-0004-z. [Epub ahead of print]

PMID:
28528518
2.

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.

Cheng DT, Prasad M, Chekaluk Y, Benayed R, Sadowska J, Zehir A, Syed A, Wang YE, Somar J, Li Y, Yelskaya Z, Wong D, Robson ME, Offit K, Berger MF, Nafa K, Ladanyi M, Zhang L.

BMC Med Genomics. 2017 May 19;10(1):33. doi: 10.1186/s12920-017-0271-4.

3.

RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage.

Paul A, Wang B.

Mol Cell. 2017 May 18;66(4):458-472.e5. doi: 10.1016/j.molcel.2017.04.013.

PMID:
28525740
4.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.

Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.

Oncotarget. 2017 May 4. doi: 10.18632/oncotarget.17613. [Epub ahead of print]

5.

Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire.

Hebestreit K, Yahiaoui-Doktor M, Engel C, Vetter W, Siniatchkin M, Erickson N, Halle M, Kiechle M, Bischoff SC.

BMC Cancer. 2017 May 18;17(1):341. doi: 10.1186/s12885-017-3337-y.

6.

Drugging the Cancers Addicted to DNA Repair.

Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059.

PMID:
28521333
7.

ARID1B alterations identify aggressive tumors in neuroblastoma.

Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW.

Oncotarget. 2017 Apr 28. doi: 10.18632/oncotarget.17500. [Epub ahead of print]

8.

Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H.

J Clin Oncol. 2017 May 17:JCO2016719260. doi: 10.1200/JCO.2016.71.9260. [Epub ahead of print]

PMID:
28514183
9.

Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.

Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y, Yang XH.

J Cell Biochem. 2017 May 17. doi: 10.1002/jcb.26140. [Epub ahead of print]

PMID:
28513990
10.

Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics.

Mahmood K, Jung CH, Philip G, Georgeson P, Chung J, Pope BJ, Park DJ.

Hum Genomics. 2017 May 16;11(1):10. doi: 10.1186/s40246-017-0104-8.

11.

Frequency of Germline BRCA1/2 Mutations in Unselected Patients With Colorectal Cancer.

Daniels MS, Bannon SA, Mork ME.

J Clin Oncol. 2017 May 16:JCO2017727222. doi: 10.1200/JCO.2017.72.7222. [Epub ahead of print] No abstract available.

PMID:
28510492
12.

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T.

Int J Clin Oncol. 2017 May 15. doi: 10.1007/s10147-017-1137-7. [Epub ahead of print] Review.

PMID:
28508305
13.

A strategy to apply quantitative epistasis analysis on developmental traits.

Labocha MK, Yuan W, Aleman-Meza B, Zhong W.

BMC Genet. 2017 May 15;18(1):42. doi: 10.1186/s12863-017-0508-4.

14.

Application of Panel-Based Tests for Inherited Risk of Cancer.

Shah PD, Nathanson KL.

Annu Rev Genomics Hum Genet. 2017 May 15. doi: 10.1146/annurev-genom-091416-035305. [Epub ahead of print]

PMID:
28504904
15.

Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.

Rummel SK, Lovejoy L, Shriver CD, Ellsworth RE.

Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4291-8. [Epub ahead of print]

PMID:
28503720
16.

Radiation and depression associated with complications of tissue expander reconstruction.

Chuba PJ, Stefani WA, Dul C, Szpunar S, Falk J, Wagner R, Edhayan E, Rabbani A, Browne CH, Aref A.

Breast Cancer Res Treat. 2017 May 13. doi: 10.1007/s10549-017-4277-6. [Epub ahead of print]

PMID:
28503719
17.

Biochemical and biophysical characterization of ruthenation of BRCA1 RING protein by RAPTA complexes and its E3 ubiquitin ligase activity.

Temboot P, Lee RFS, Menin L, Patiny L, Dyson PJ, Ratanaphan A.

Biochem Biophys Res Commun. 2017 May 10. pii: S0006-291X(17)30914-2. doi: 10.1016/j.bbrc.2017.05.052. [Epub ahead of print]

PMID:
28501617
18.

[Hereditary breast and ovarian cancer].

Lax SF.

Pathologe. 2017 May;38(3):149-155. doi: 10.1007/s00292-017-0298-5. Review. German.

PMID:
28500412
19.

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.

Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.

BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-017-3283-8.

20.

Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Aβ1-42-Induced Neurotoxicity and Cognitive Deficits.

Dai R, Zhang S, Duan W, Wei R, Chen H, Cai W, Yang L, Wang Q.

Neurochem Res. 2017 May 12. doi: 10.1007/s11064-017-2266-0. [Epub ahead of print]

PMID:
28497346

Supplemental Content

Loading ...
Support Center